Introduction: There is limited published literature on longitudinal utilization of glucose-lowering agents (GLAs) among patients with type 2 diabetes (T2D) and cardiovascular disease (CVD or risk of CVD). This retrospective, observational study aimed to provide updated evidence on patient characteristics and utilization of GLAs among patients with T2D and CVD or risk of CVD in the United States.
Methods: This was a cross-sectional evaluation of patients with T2D aged 50-89 years with annual continuous enrolment in a Medicare Advantage and Prescription Drug plan, identified from administrative claims data (Humana Research Database). Patients with T2D and atherosclerotic cardiovascular disease (ASCVD) or heart failure (HF) (CVD cohort), or T2D and an additional CVD risk factor without pre-existing CVD (CVD risk cohort) were identified from 2015 to 2019. Patients were followed from their first observed ASCVD/HF diagnosis or CVD risk factor for each year they were continuously enrolled or until occurrence of a CVD diagnosis (CVD risk cohort only). Use of GLA classes were reported by year, cohort, and age groups (50-64 years and ≥ 65 years).
Results: The percentage of patients on sodium-glucose co-transporter-2 inhibitors (SGLT-2is), glucagon-like peptide-1 receptor agonists (GLP-1 RAs), and GLP-1 RAs with proven cardiovascular benefit, respectively, increased from 2015 to 2019 among ≥ 65 years (CVD cohort: 1.1-3.4%, 1.6-4.0%, and 1.2-3.8%; CVD risk cohort: 1.4-3.7%, 2.0-4.3%, and 1.5-4.1%); and among 50-64 years (CVD cohort: 2.6-7.3%, 4.3-10.1%, and 3.4-9.4%; CVD risk cohort: 3.3-6.8%, 4.6-9.6%, and 3.5-8.9%).
Conclusions: Although use of SGLT-2is and GLP-1 RAs increased over time, overall utilization of these agents in patients with T2D and ASCVD/HF or at risk for ASCVD/HF remained low, especially for those aged ≥ 65 years.
Keywords: Cardiovascular disease; Glucagon-like peptide-1 receptor agonists; Sodium-glucose co-transporter-2 inhibitors; Treatment patterns; Type 2 diabetes.
Sodium-glucose co-transporter-2 inhibitors (SGLT-2is) and glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are types of glucose-lowering medications for patients with type 2 diabetes (T2D). The American Diabetes Association, the American Association of Clinical Endocrinologists, and American College of Endocrinology have recommended these medications for patients who have been diagnosed with T2D and atherosclerotic cardiovascular disease or heart failure (ASCVD/HF). The purpose of this study was to find out how many patients in a US-based health insurance population with T2D and ASCVD/HF were treated with SGLT-2is, GLP-1 RAs, and other glucose-lowering medications from 2015 to 2019. Using insurance claims data, we identified 50- to 89-year-old patients with T2D and either ASCVD/HF or at least one risk factor for ASCVD/HF. We tracked the number of patients with T2D and either ASCVD/HF or ASCVD/HF risk factors who were using different glucose-lowering medications. Glucose-lowering medications were used in most patients (60–78%), but fewer than 11% of patients aged 50–64 years, and fewer than 5% of patients over 65 years of age were prescribed SGLT-2i and GLP-1 RA medications, despite clinical guidelines recommending their use for the above-mentioned indications. Increasing awareness among healthcare providers may be required to ensure patients with T2D and ASCVD/HF or ASCVD/HF risk factors are prescribed the guideline-recommended cardioprotective glucose-lowering agents.
© 2022. The Author(s).